Table 6 Associations at relapse of... | American Society of Hematology

Table 6

Associations at relapse of patients with PRα/LBD and FLT3 mutations (n = 41*) or ACAs (n = 21) by univariate analysis

Test parameter	PRα/LBD mutations (18 vs 23*)		FLT3-ITD mutations (15 vs 26*)		FLT3-D835 mutations (5 vs 36*)		ACA (13 vs 8*)
Test parameter	Descriptor	P	Descriptor	P	Descriptor	P	Descriptor	P
Presenting WBCs	Low	.03	High	.006	—	ANI	—	ANI
Time to relapse	—	ANI	ANI	ANI	Shorter	< .001	—	ANI
Relapse On-ATRA†	Increased incidence	.06	—	ANI	—	.15‡	—	ANI
Postrelapse death	—	ANI	—	ANI	—	ANI	Increased Incidence	.05
PML-RARα type	—	ANI	↑ S-isoform incidence	< .001	—	ANI	↑ L-isoform incidence	.07
FLT3-ITD⁺	—	ANI	—	—	—	ANI	Negative association	.003
ACA	—	ANI	Negative association	.003	—	ANI	—	ANI

Test parameter	PRα/LBD mutations (18 vs 23*)		FLT3-ITD mutations (15 vs 26*)		FLT3-D835 mutations (5 vs 36*)		ACA (13 vs 8*)
Test parameter	Descriptor	P	Descriptor	P	Descriptor	P	Descriptor	P
Presenting WBCs	Low	.03	High	.006	—	ANI	—	ANI
Time to relapse	—	ANI	ANI	ANI	Shorter	< .001	—	ANI
Relapse On-ATRA†	Increased incidence	.06	—	ANI	—	.15‡	—	ANI
Postrelapse death	—	ANI	—	ANI	—	ANI	Increased Incidence	.05
PML-RARα type	—	ANI	↑ S-isoform incidence	< .001	—	ANI	↑ L-isoform incidence	.07
FLT3-ITD⁺	—	ANI	—	—	—	ANI	Negative association	.003
ACA	—	ANI	Negative association	.003	—	ANI	—	ANI

Detailed data for all parameters are listed in “Statistical methods” and in supplemental Table 9. Descriptor indicates the nature of the association of the test parameter with the aberration in the heading.

— indicates not applicable; and ANI, association not indicated.

Number positive vs number negative.

†

Relapse On-ATRA, relapse within 30 days of last dose of ATRA.

‡

Four of 5 patients (80%) with FLT3-D835⁺ versus 14 of 36 patients (39%) without FLT3-D835⁺ relapsed On-ATRA (P = 0.15).

View Large

This Feature Is Available To Subscribers Only